Some good news: A Phase 3 clinical trial of what could be the first new #tuberculosis vaccine in over 100 years has been able to enroll all needed participants months ahead of schedule. https://t.co/SbirAPni0V
Great piece of clear, accesible sci comms by @devisridhar progress made & still to be made against drug-resistance infections (or AMR), and challenges for developing new drugs 💊
https://t.co/R7cP7Z7Y8H
“Local, equitable response to endemic disease outbreaks is the key to a rapid, effective pandemic response.”
@wellcometrust's Natsuko Imai on strengthening epidemic responses & research to be prepared for the next pandemic, in @devex.
👇 https://t.co/D8ED0lRKQc
Human challenge trials have the power to rapidly accelerate the development of much-needed vaccines and treatments.
Dr Kondwani Jambo (@kjambo), an expert on the topic at @MLW_Programme, explains more ⤵️
Antimicrobial resistance (AMR) is a growing global health threat.
Without urgent action, bacterial AMR will account for three deaths every minute between 2025 and 2050.
The latest GRAM report in @TheLancet gives vital new evidence. Read on for key takeaways ⤵️ [1/3]
“The world cannot be complacent. Pathogens don’t recognize borders, and neither should our efforts to improve global health.”
@jarottingen@wellcometrust@politico
👇 https://t.co/3NecLAnlUy
Can comms solve the spread of disinformation? 📝👂🗣️
Insightful discussion on building trust in communities through transparency, involving those affected in research & improving access to products, to fill the gaps before misinformation can.
#WHA77 @PandemicAction @gabbystern
Antimicrobial resistance is associated with thousands of preventable deaths each year.
Great to hear from @UKAMREnvoy on the need for strengthening public confidence & evidence-based vaccine development as part of the global response to #AMR.
@IVIHeadquarters#WHA77
"In the context of the inequality in the world, we will need a vaccine to control #tuberculosis” 💉🌍
A great explanation of the challenges facing TB control and vaccine development, and hopes for the M72 candidate.
👇@wellcometrust@GSK@AHRI_News
https://t.co/BnRHmTVFWs
Collaboration will accelerate the discovery of solutions to urgent health challenges.
Here’s why we’re excited to be partnering with @novonordiskfond and @gatesfoundation on a new initiative to support critical research and development.
🧵[1/6]
African communities are often the most affected by infectious diseases.
So what challenges do African countries face fin building expertise & vaccine manufacturing capabilities?
@DrCharlieWeller
https://t.co/ABqjXDCFz1
In the fight against infectious diseases, the voices of those most affected are a powerful tool.
The Africa Health Research Institute (@AHRI_News) aims to combat diseases like TB by working with local communities.
Experts at AHRI explain why this context is key for research ⤵️
A potential vaccine candidate for tuberculosis, supported by Wellcome and @gatesfoundation, has started its Phase 3 clinical trial in South Africa.
If shown to be well-tolerated and effective, the vaccine could become the first tuberculosis vaccine in over a century.
So exciting to see positive news of a safe and effective #malaria vaccine to protect children in African countries! Accessible & affordable products are key to achieving #globalheath equity 🌍💉
@Independent 👉 https://t.co/dsm24rzbzV
In the decade since the 'AMR review', there's been little concrete action to address this #globalhealth crisis.
Could setting tangible targets and holding decision makers to account help drive progress?
https://t.co/WVYFAwgqEG
@wellcometrust@_Jeremy_Knox@novonordisk
The @COP28_UAE agreement represents a united global demand to protect human health and halt the climate crisis.
We must build on the momentum from the first-ever Health Day at #COP28 to garner bolder, faster and healthier climate action.
Today, the @WHO released its annual report on the state of tuberculosis (TB).
The topline?
TB is still one of the world's deadliest infectious diseases — and the funding needed to change that is falling well short.
But there's been some promising progress... [1/5]🧵⤵️